

type of report	Current report
number	64/2012
company	PHARMENA

**Entering into agreement with an audit firm with relation to public offering of series D shares**

The Management Board of PHARMENA S.A. informs that on 10<sup>th</sup> October 2012, pursuant to the resolution of the Supervisory Board of 27<sup>th</sup> September 2012 on appointment of an auditor, the Company entered into agreement with audit firm BDO Sp. z o.o., with registered office in Warsaw, ul. Postępu 12. The appointed firm is to carry out audit of consolidated financial statements of Capital Group PHARMENA S.A. for the years 2009-2011, for the purposes of the public offering of series D shares planned for Q1 2013. The goal of issue of series D shares is to obtain funds for clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of phase II ("Proof of Concept").

BDO Sp. z o.o. is registered in the National Chamber of Statutory Auditors on the list of entities authorized to audit financial statements under the number 3355.

The information is made public due to fact that entering into agreement with an auditor is necessary to perform public offering of series D shares, which goal is to obtain funds for clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of phase II ("Proof of Concept"). Potential revenue from commercialisation of the above project will have significant influence on the Issuer's financial situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (2.2).

**Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board